bluuebunny/crossref_metadata_2025_split huggingface dataset:
Efficacy of a low dose fipronil bait against blacklegged tick (Ixodes scapularis) larvae feeding on white-footed mice (Peromyscus leucopus) under laboratory conditions
Authors: Poché David M. , Franckowiak Gregory , Clarke Tyler , Tseveenjav Batchimeg , Polyakova Larisa , Poché Richard M. 
Published: July 2020

AbstractBackgroundLyme disease is the most prevalent vector-borne disease in the USA with cases continuing to increase. Current control measures have not been shown to be impactful, and therefore alternatives are needed. Treating pathogen reservoirs with low dose systemic acaricides in endemic areas may provide a useful tool for disrupting the cycle of the vector and pathogen. The purpose of this study was to determine the efficacy of a 0.005% fipronil bait, presented orally to white-footed mice, in controlling blacklegged tick larvae (larvae).MethodsSixty mice were assigned to 3 treatment groups and three untreated control groups. All individually housed mice in treatment groups were exposed to 0.005% fipronil bait for 48 hours. Larvae were manually applied to mice within feeding capsules at one of three timepoints: Day 1, Day 9 and Day 15 post-exposure. For 4-days post-tick attachment, replete larvae were collected from water moats underneath each cage and attached larvae were observed by microscopy. Plasma from 4 treated mice at Day-1, Day 13 and Day 19, and 4 control mice (n = 16) was collected to obtain fipronil plasma concentrations (CP).ResultsFipronil bait did not appear to produce neophobia in mice, as the amount of bait eaten at 24- and 48-hours exposure did not differ significantly. The 48-hour fipronil bait exposure prevented 100% of larvae from feeding to repletion at Day 1, Day 9 and Day 15 post-treatment. Within the treatment groups, all larvae observable within the capsules expired and were prevented from detaching by Day 4. In contrast, within the control groups a total of 502 replete larvae were collected from moats and 348 larvae observable within the capsules successfully detached. CP averaged 948.9, 101.2 and 79.4 ng/ml for mice euthanized at Day 1, Day 9 and Day 15, respectively. No fipronil was detected in control mice.ConclusionsWe provide early indication that low dose fipronil bait, orally presented to white-footed mice, can effectively control blacklegged tick larvae. Future research should modify the exposure duration and post-exposure tick attachment timepoints to simulate various field scenarios under which successful efficacy might be obtained. Low dose fipronil bait could provide a cost-effective, practical means of controlling blacklegged ticks and other arthropod vectors.
Identification of protective peptides of Fasciola hepatica-derived cathepsin L1 (FhCL1) in vaccinated sheep by a linear B-cell epitope mapping approach
Authors: Buffoni Leandro , Garza-Cuartero Laura , Pérez-Caballero Raúl , Zafra Rafael , Javier Martínez-Moreno F. , Molina-Hernández Verónica , Pérez José , Martínez-Moreno Álvaro , Mulcahy Grace 
Published: July 2020

AbstractBackgroundFasciolosis is one of the most important parasitic diseases of livestock. The need for better control strategies gave rise to the identification of various vaccine candidates. The recombinant form of a member of the cysteine protease family, cathepsin L1 ofFasciola hepatica(FhCL1) has been a vaccine target for the past few decades since it has been shown to behave as an immunodominant antigen. However, when FhCL1 was used as vaccine, it has been observed to elicit significant protection in some trials, whereas no protection was provided in others.MethodsIn order to improve vaccine development strategy, we conducted a linear B-cell epitope mapping of FhCL1 in sheep vaccinated with FhCL1, FhHDM, FhLAP and FhPrx plus Montanide and with significant reduction of the fluke burden, sheep vaccinated with FhCL1, FhHDM, FhLAP and FhPrx plus aluminium hydroxide and with non-significant reduction of the fluke burden, and in unvaccinated-infected sheep.ResultsOur study showed that the pattern and dynamic of peptide recognition varied noticeably between both vaccinated groups, and that the regions 55–63 and 77–84, which are within the propeptide, and regions 102–114 and 265–273 of FhCL1 were specifically recognised only by vaccinated sheep with significant reduction of the fluke burden. In addition, these animals also showed significant production of specific IgG2, whereas a scarce non-significant production was observed in animals vaccinated with Aluminium hydroxide and no production was detected in infected control animals.ConclusionsWe have identified 42 residues of FhCL1 that contributed to protective immunity against infection withF. hepaticain sheep. Our results provide indications in relation to key aspects of the immune response. Given the variable outcomes of vaccination trials conducted in ruminants to date, this study adds new insights to improve strategies of vaccine development.
Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis
Authors: Kwon Oh Chan , Park Jung Hwan , Park Yong-Beom , Park Min-Chan 
Published: July 2020

Abstract
Background
To identify disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis (TAK).

Methods
Patients with TAK who fulfilled the American College of Rheumatology 1990 criteria for the classification of TAK and were followed up between 2006 and 2019 were included. Traditional cardiovascular risk factors and TAK disease-specific factors at the index date and incident cardiovascular events during the follow-up were retrospectively assessed. To estimate the risk of cardiovascular events according to TAK disease-specific factors, Cox regression analysis with adjustment for traditional cardiovascular risk factors was performed.

Results
Of the total 207 patients with TAK, cardiovascular events occurred in 41 (19.8%) patients. Compared with patients who did not develop cardiovascular events, patients who developed cardiovascular events were older (38.5 ± 13.4 years vs. 43.6 ± 11.8 years, p = 0.028), more commonly had diabetes mellitus (6.6% vs. 19.5%, p = 0.029), had lower high-density lipoprotein cholesterol (57.3 ± 17.1 mg/dl vs. 51.2 ± 15.7 mg/dl, p = 0.040), more commonly had type V vascular involvement (33.1% vs. 63.4%, p 0.001), and less commonly received methotrexate (65.1% vs. 43.9%, p = 0.013). In Cox regression analysis, type V vascular involvement was significantly associated with increased risk of cardiovascular events (adjusted HR 2.852, 95% CI 1.474–5.518, p = 0.002), whereas the use of methotrexate was associated with reduced risk of cardiovascular events (adjusted HR 0.515, 95% CI 0.268–0.993, p = 0.047).

Conclusion
Type V vascular involvement was associated with increased risk of cardiovascular events, while the use of methotrexate was associated with reduced risk of cardiovascular events, in patients with TAK.
Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes
Authors: DiBenedetti Dana B. , Slota Christina , Wronski Samantha L. , Vradenburg George , Comer Meryl , Callahan Leigh F. , Winfield John , Rubino Ivana , Krasa Holly B. , Hartry Ann , Wieberg Dan , Kremer Ian N. , Lappin Debra , Martin Allison D. , Frangiosa Terry , Biggar Virginia , Hauber Brett 
Published: July 2020

Abstract
Background
The What Matters Most (WMM) study was initiated to evaluate symptoms, AD-related impacts, treatment-related needs, preferences, and priorities among individuals with or at risk for Alzheimer’s disease (AD) and their care partners. The objective of this qualitative study phase was to identify a comprehensive set of concepts of interest that are meaningful to individuals across the AD continuum.

Methods
Interviews were conducted with 60 clinically referred individuals and care partners across 5 AD stages (n = 12 each): group 1 (non-clinically impaired individuals with AD pathology), group 2 (individuals with mild cognitive impairment and AD pathology), group 3 (individuals with mild AD), group 4 (individuals with moderate AD and their care partners), and group 5 (care partners of individuals with severe AD). Interviews were conducted by experienced interviewers, audio-recorded, and transcribed. Dominant trends were identified in each interview and compared across subsequent interviews to generate themes or patterns in descriptions of AD symptoms, impacts, and desired treatment outcomes.

Results
All participants endorsed current issues related to memory; nearly all participants (n = 55; 92%) across the five groups endorsed symptoms related to communication and language. Groups 1–3 reported an impact on mood/emotions (n = 23; 64%) and a decrease in social activities or outgoingness (n = 17; 47%). Current and future concerns reported by the overall sample included memory (n = 48; 80%), dependence (n = 40; 67%), and “other” concerns (n = 33; 55.0%) (e.g., uncertainty about the future, burdening others). The most desired AD treatment outcomes were improvement or restoration of memory (n = 40; 67%) and stopping AD progression (n = 35; 58.3%). Group-level differences were observed in the symptoms, impacts, and desired treatment outcomes among patients and care partners across the AD continuum.

Conclusions
Cognitive functioning issues—particularly in memory and communication—are present even in preclinical and early-stage AD, including among those without a formal AD diagnosis. While the impacts of AD vary across the disease-severity spectrum, improved memory and disease modification were treatment outcomes considered most important to participants across all 5 AD stages. Neuropsychological assessments traditionally used in AD clinical trials may not evaluate the often-subtle concepts that are important to patients and care partners. Results from this study will inform the second phase of the WMM project—a quantitative study to elicit the relative importance of these concepts of interest to people at risk for and living with AD and their care partners.
Exposure to Toxocara spp. and Ascaris lumbricoides infections and risk of allergic rhinitis in children
Authors: Mohammadzadeh Iraj , Darvish Sorena , Riahi Seyed Mohammad , Moghaddam Solmaz Alizadeh , Pournasrollah Mohammad , Mohammadnia-Afrozi Mousa , Rostami Ali 
Published: July 2020

Abstract
Background
Substantial experimental studies suggest a role for helminthes infections in the pathogenesis of allergies, but epidemiologic data have been inconsistent. Unlike to asthma, the association between helminthes infection and allergic rhinitis (AR) has been poorly studied. Therefore, we sought to evaluate the association between exposure to Ascaris and Toxocara infections and AR.

Methods
We did an age- and gender-matched case–control study of 81 children with physician-confirmed AR and 101 control subjects in a referral hospital for pediatric diseases in northern Iran. Exposure to Ascaris and Toxocara infections was evaluated by anti-A. lumbricoides- and anti-Toxocara- IgG antibodies using a commercial enzyme-linked immunosorbent assay. Associations were determined using multivariate logistic regression.

Results
Ascaris seropositivity was higher in children with rhinitis than in controls (12.34 vs. 3.96%). Ascaris seropositivity was positively associated with AR in univariate analysis (OR, 3.42; 95% CI 1.03–11.3; P value = 0.035), but this association was not significant after adjustment for potential confounders (OR, 1.85; 95% CI 0.42–8.18). Also Toxocara seropositivity was higher in children with AR than in healthy subjects (3.7% vs. 0.99), indicating non-significant association with AR in both univariate (OR, 3.84; 95% CI 0.39–37.7) and multivariate analyses (OR, 0.8; 95% CI 0.04–15.44).

Conclusion
Our results revealed that AR is not associated with seropositivity to Ascaris and Toxocara infections in general; however, a higher seropositivity rate was found for both parasites in children with AR. More studies with longitudinal design and larger sample size are needed to elucidate this association.
Parathyroid hormone (1-34) promotes the effects of 3D printed scaffold-seeded bone marrow mesenchymal stem cells on meniscus regeneration
Authors: Zhao Wen , Zou Tong , Cui Hao , Lv Yangou , Gao Dengke , Ruan Chenmei , Zhang Xia , Zhang Yihua 
Published: July 2020

AbstractBackgroundCell-based tissue engineering represents a promising management for meniscus repair and regeneration. The present study aimed to investigate whether the injection of parathyroid hormone (PTH) (1-34) could promote the regeneration and chondroprotection of 3D printed scaffold seeded with bone marrow mesenchymal stem cells (BMSCs) in a canine total meniscal meniscectomy model.Methods3D printed poly(e-caprolactone) scaffold seeded with BMSCs was cultured in vitro, and the effects of in vitro culture time on cell growth and matrix synthesis of the BMSCs–scaffold construct were evaluated by microscopic observation and cartilage matrix content detection at 7, 14, 21, and 28 days. After that, the tissue-engineered meniscus based on BMSCs–scaffold cultured for the appropriate culture time was selected for in vivo implantation. Sixteen dogs were randomly divided into four groups: PTH + BMSCs–scaffold, BMSCs–scaffold, total meniscectomy, and sham operation. The regeneration of the implanted tissue and the degeneration of articular cartilage were assessed by gross, histological, and immunohistochemical analysis at 12 weeks postoperatively.ResultsIn vitro study showed that the glycosaminoglycan (GAG)/DNA ratio and the expression of collagen type II (Col2) were significantly higher on day 21 as compared to the other time points. In vivo study showed that, compared with the BMSCs–scaffold group, the PTH + BMSCs–scaffold group showed better regeneration of the implanted tissue and greater similarity to native meniscus concerning gross appearance, cell composition, and cartilage extracellular matrix deposition. This group also showed less expression of terminal differentiation markers of BMSC chondrogenesis as well as lower cartilage degeneration with less damage on the knee cartilage surface, higher expression of Col2, and lower expression of degeneration markers.ConclusionsOur results demonstrated that PTH (1-34) promotes the regenerative and chondroprotective effects of the BMSCs–3D printed meniscal scaffold in a canine model, and thus, their combination could be a promising strategy for meniscus tissue engineering.
Chronic arsenic exposure induces the time-dependent modulation of inflammation and immunosuppression in spleen
Authors: Yan Nan , Xu Guowei , Zhang Chenchen , Liu Xuping , Li Xin , Sun Lin , Wang Da , Duan Xiaoxu , Li Bing 
Published: July 2020

Abstract
Background
Arsenic exposure has become a matter of worldwide concern, which is associated with immune-related diseases. However, little is known about its effect on inflammatory immune-related homeostasis. The purpose of our study was to understand the potential tuning of above responses exerted by chronic arsenic exposure.

Methods
Kunming mice were treated with 25 and 50 mg/L sodium arsenite for 1, 3 and 12 months via drinking water. At different endpoints of arsenic exposure, all animals and the whole spleen of the mice were weighed. The total arsenic levels of spleen were determined by the HPLC-HG-AFS method. Splenic NF-κB, MAPK and NRF2 protein levels by treatment of 25 mg/L NaAsO2 for 1, 3 and 12 months and 25 mg/L and 50 mg/L NaAsO2 for 12 months were assessed by western blot. Total RNA of spleen was isolated and relative mRNA levels of Foxp3, Il-10, Tnf-α, Il-6, Ifn-γ, Il-1β and Il-12 were measured by real-time PCR.

Results
Our results shown that NF-κB were continuously activated with treatment of 25 mg/L arsenic from 1, 3 to 12 months and 50 mg/L arsenic for 12 months. The transcription factor Foxp3 increased at 1 month but decreased at 3 and 12 months no matter 25 or 50 mg/L arsenic exposure. However, cytokine Il-10 always showed increased trend in mice treated with 25 or 50 mg/L arsenic for 1, 3 and 12 months. The transcriptional profiles of Tnf-α, Il-1β, Il-6, Ifn-γ and Il-12 revealed transient elevation at 1 and 3 months but shown significant decrease at 12 months on the whole. In addition, the sustained activation of inflammatory MAPK and anti-oxidative Nrf2 signaling pathways were observed in mice exposed to arsenic for 1, 3 and 12 months.

Conclusion
In summary, our experiment in vivo suggested chronic arsenic exposure induces the time-dependent modulation of the inflammation and immunosuppression in spleen, which may be related to the activation of Tregs induced by MAPK/NF-κB as well as the increased transcription level of Foxp3 and Il-10.
Simplified Constitutive and Damage Plasticity Models for UHPFRC with Different Types of Fiber
Authors: Hashim Doaa Talib , Hejazi Farzad , Lei Voo Yen 
Published: July 2020

AbstractIn this study, several simplified constitutive models and a damage plasticity model for ultra-high performance fiber reinforced concrete(UHPFRC)material with micro and hooked ends steel fibers, Bekaert Dramix 5D steel fiber, and Forta-Ferro synthetic fiber had been developed. Later, these constitutive and damage plasticity models were applied as analytical model to numerically simulate the concrete members with different fibers, and to evaluate the behavior of the concrete sections. The constitutive models for UHPFRC of three mix designs were obtained experimentally by conducting uniaxial compression and tensile tests on both cylinder and dog-bone specimens. Next, a comparison was made among the three mix designs based on the outcomes retrieved from uniaxial compression and tensile stress–strain. These results were validated by numerically analyzing three hollow circular columns via finite element method. The numerical results revealed that the proposed material model possessed appropriate tensile strain-hardening behavior and uniaxial compression strengths of UHPFRC with different types of fiber. The lateral resistance responses of the tested hollow sections, which were obtained by using developed constitutive and damage plasticity models, displayed exceptional agreement with the experimental outcomes.
“Universal test and treat” program reduced TB incidence by 75% among a cohort of adults taking antiretroviral therapy (ART) in Gurage zone, South Ethiopia
Authors: Girum Tadele , Yasin Fedila , Dessu Samuel , Zeleke Bereket , Geremew Mulugeta 
Published: July 2020

Abstract
Background
Tuberculosis (TB) remains the leading cause of morbidity and mortality in peoples living with HIV and at least 25% of deaths are attributed to TB. Many countries implement the Universal Test and Treat (UTT) program for HIV, which is believed to reduce the incidence of TB. However, there are limited studies that evaluate the impact of UTT on TB incidence. Therefore, by recruiting a cohort of ART users in the “UTT” and “differed treatment” programs, we aim to measure the effect of the UTT program on TB incidence.

Objective
To measure the effect of “UTT” program on TB incidence among a cohort of adults taking antiretroviral therapy (ART) in Gurage Zone, South Ethiopia.

Methods
A retrospective cohort study was conducted through record review over 5 years (2014–2019) in public health facilities in Gurage Zone. Three hundred eighty-four records were randomly selected and reviewed using a standardized structured checklist. Data was entered using Epi Info™ Version 7 and analyzed by STATA. A generalized linear model with binomial link function was fitted to measure the adjusted incidence density/incidence rate ratio and to identify predictors of incidence difference between the two programs.

Results
During the follow up period, 39 incident TB cases were identified with an overall incidence rate of 4.79/100 person-year (PY). TB incidence was significantly lower in the UTT cohort (IR = 2.10/100 PY) in comparison to the differed program cohort (IR = 6.23/100 PY). The adjusted incidence rate ratio (AIRR) of TB among patients enrolled in the UTT program was; 0.25 (95% CI = 0.08–0.70). Thus, there was a reduction of TB incidence by 75% in the UTT program compared to differed program. In addition, IPT (isoniazid preventive therapy) use (AIRR = 0.35 (95% CI = 0.22–0.48)), WHO Stage I and II (AIRR = 0.70 (95% CI = 0.61–0.94)) and higher base line CD4 count (AIRR = 0.96 (95% CI = .94–0.99)) significantly reduced the incidence of TB. However, treatment failure increase the incidence (AIRR = 5.8 (95% CI = 1.93–8.46)).

Conclusion
TB incidence was significantly reduced by 75% after UTT. Therefore, intervention to further reduce the incidence has to focus on strengthening UTT program and IPT.
A study of efficacy and safety of tranexamic acid versus iodopovidone in pleurodesis via pigtail catheter in management of recurrent pleural effusion
Authors: Abd El Zaher Ayman H. , El Dib Ayman S. 
Published: July 2020

Abstract
Background
Researches to detect the ideal agent for pleurodesis are still continuous; iodopovidone is one of the best agents for pleurodesis that are commonly used. Tranexamic acid is also considered by many authors as a safe, cheap, and effective agent for pleurodesis.

Results
Group I (patients subjected to pleurodesis using tranexamic acid) had a higher complete response with a success rate 88% compared with 76% for group II (patients subjected to pleurodesis using iodopovidone) at the end of the study in 12 weeks. Complications were nearly equal in both groups. Chest pain, hypotension, and fever were the most common reported complications.

Conclusions
Tranexamic acid and iodopovidone were found to be effective alternative agents for pleurodesis with low cost and minimal complications.
Treatment Options for Gonadotroph Tumors: Current State and Perspectives
Authors: Ilie Mirela Diana , Raverot Gérald 
Published: July 2020

Abstract

Context
Gonadotroph tumors represent approximatively one-third of anterior pituitary tumors, but despite their frequency, no medical treatment is currently recommended for them. This would be greatly needed because following surgery, which is the first-line treatment, a significant percentage of gonadotroph tumors regrow.

Evidence Acquisition
We performed PubMed searches in March 2020 using the term “gonadotroph” in combination with 36 different keywords related to dopamine type 2 receptor agonists, somatostatin receptor (SST) ligands, temozolomide, peptide receptor radionuclide therapy (PRRT), immunotherapy, vascular endothelial growth factor receptor (VEGFR)-targeted therapy, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors. Articles resulting from these searches, as well as relevant references cited by these articles were reviewed.

Evidence Synthesis
SST2 analogs have demonstrated only very limited antitumor effect, while high-dose cabergoline has been more effective in preventing tumor regrowth, but still in only a minority of cases. In the setting of an aggressive gonadotroph tumor, temozolomide is the recommended medical treatment, but has demonstrated also only limited efficacy. Still, its efficacy has been so far better than that of PRRT. No case of a gonadotroph tumor treated with pasireotide, VEGFR-targeted therapy, mTOR inhibitors, tyrosine kinase inhibitors, or immune checkpoint inhibitors is reported in literature.

Conclusions
Gonadotroph tumors need better phenotyping in terms of both tumor cells and associated tumor microenvironment to improve their treatment. Until formal recommendations will be available, we provide the readers with our suggested approach for the management of gonadotroph tumors, management that should be discussed within multidisciplinary teams.